David A. Siegel Inmune Bio, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Inmune Bio, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 12,700 shares of INMB stock, worth $117,094. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,700Holding current value
$117,094% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding INMB
# of Institutions
78Shares Held
7.04MCall Options Held
202KPut Options Held
42.9K-
Black Rock Inc. New York, NY813KShares$7.49 Million0.0% of portfolio
-
Praetorian Pr LLC Rincon, PR812KShares$7.49 Million1.52% of portfolio
-
Vanguard Group Inc Valley Forge, PA738KShares$6.81 Million0.0% of portfolio
-
Cvi Holdings, LLC Wilmington, DE596KShares$5.5 Million45.87% of portfolio
-
Raymond James Financial Inc St. Petersburg, FL476KShares$4.38 Million0.0% of portfolio
About Inmune Bio, Inc.
- Ticker INMB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,946,000
- Market Cap $165M
- Description
- INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on tr...